The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass
Abstract
CONTEXT: Denosumab treatment for 24 months increased bone mineral density (BMD) and reduced bone turnover markers (BTM) in postmenopausal women. OBJECTIVE: The aim was to determine the effects of prior denosumab or placebo injections on BMD, BTM, and safety over 24 months after treatment discontinuation. DESIGN: We conducted an off-treatment extension of a phase 3, randomized, double-blind, parallel-group study. PARTICIPANTS: A total of 256 postmenopausal women with a mean age of 59 yr and a mean lumbar spine T-score of -1.61 at randomization participated in the study. INTERVENTIONS: Participants received placebo or 60 mg denosumab every 6 months for 24 months, followed by 24 months off treatment. MAIN OUTCOME MEASURES: We measured the percentage changes in BMD and BTM, and evaluated safety. RESULTS: Of the 256 participants enrolled in the posttreatment phase, 87% completed the study. During 24 months of denosumab treatment, BMD increased (lumbar spine, 6.4%; total hip, 3.6%; 1/3 radius, 1.4%), and BTM decreased (serum C-terminal telopeptide of type 1 collagen, 63%; and N-terminal propeptide of type 1 procollagen, 47%), compared with placebo. After discontinuation, BMD declined, but the previously treated denosumab group maintained higher BMD than the previously treated placebo group at these sites (P ≤ 0.05). Final BMD at month 48 strongly correlated with month 0 BMD. After denosumab discontinuation, BTM increased above baseline within 3 months (serum C-terminal telopeptide of type 1 collagen) or 6 months (N-terminal propeptide of type 1 procollagen) and returned to baseline by month 48. Adverse event rates during the off-treatment phase were similar between groups. CONCLUSIONS: In postmenopausal women with low BMD, the effects of 60 mg denosumab treatment for 24 months on BMD and BTM are reversible upon discontinuation, reflecting its biological mechanism of action. Residual BMD measurements remained above those of the group previously treated with placebo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osteoporosis Prevention, Diagnosis, and Therapy
NIH Consensus Development Panel on Osteoporosis Prevention, D. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.6.785 · Cited by 5,529
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
Russell, R. G. G., Watts, N. B., Ebetino, F. H., & Rogers, M. J. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0540-8 · Cited by 1,411
Black, D. M., Schwartz, A. V., Ensrud, K. E., Cauley, J. A., Levis, S., Quandt, S. A., Satterfield, S., Wallace, R. B., Bauer, D. C., Palermo, L., et al. (2006) · JAMA · doi:10.1001/jama.296.24.2927 · Cited by 1,407
Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal Women
Bone, H. G., Hosking, D., Devogelaer, J.-P., Tucci, J. R., Emkey, R. D., Tonino, R. P., Rodriguez-Portales, J. A., Downs, R. W., Gupta, J., Santora, A. C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030897 · Cited by 1,347
Self-citationDenosumab in postmenopausal women with low bone mineral density.
McClung, M. R., Lewiecki, E. M., Cohen, S. B., Bolognese, M. A., Woodson, G. C., Moffett, A. H., Peacock, M., Miller, P. D., Lederman, S. N., Chesnut, C. H., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044459 · Cited by 1,228
Self-citationLuckman, S. P., Hughes, D. E., Coxon, F. P., Russell, R. G. G., & Dr. Rogers, M. J. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.4.581 · Cited by 1,176
Nancollas, G. H., Tang, R., Phipps, R. J., Henneman, Z., Gulde, S., Wu, W., Mangood, A., Russell, R. G. G., & Ebetino, F. H. (2006) · Bone · doi:10.1016/j.bone.2005.05.003 · Cited by 862
Role of RANK ligand in mediating increased bone resorption in early postmenopausal women
Eghbali-Fatourechi, G., Khosla, S., Sanyal, A., Boyle, W. J., Lacey, D. L., & Riggs, B. L. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17215 · Cited by 825 · cited 1×
“Excessive RANK ligand has been implicated in bone diseases associated with increased bone resorption, such as osteoporosis (23).”
BackgroundFisher, J. E., Rogers, M. J., Halasy, J. M., Luckman, S. P., Hughes, D. E., Masarachia, P. J., Wesolowski, G., Russell, R. G. G., Rodan, G. A., & Reszka, A. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.1.133 · Cited by 676
The Effect of Postmenopausal Estrogen Therapy on Bone Density in Elderly Women
Felson, D. T., Zhang, Y., Hannan, M. T., Kiel, D. P., Wilson, P., & Anderson, J. J. (1993) · New England Journal of Medicine · doi:10.1056/nejm199310143291601 · Cited by 585
Miller, P. D., Bolognese, M. A., Lewiecki, E. M., McClung, M. R., Ding, B., Austin, M., Liu, Y., & San Martin, J. (2008) · Bone · doi:10.1016/j.bone.2008.04.007 · Cited by 578
Self-citationFarnesyl Pyrophosphate Synthase Is the Molecular Target of Nitrogen-Containing Bisphosphonates
van Beek, E., Pieterman, E., Cohen, L., Löwik, C., & Papapoulos, S. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1499 · Cited by 496
Prevention and Management of Osteoporosis: Current Trends and Future Prospects
Compston, J. E. (1997) · Drugs · doi:10.2165/00003495-199753050-00001 · Cited by 487
Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women
Bone, H. G., Bolognese, M. A., Yuen, C. K., Kendler, D. L., Wang, H., Liu, Y., & San Martin, J. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2814 · Cited by 425
Self-citationHealth Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin
Heiss, G. (2008) · JAMA · doi:10.1001/jama.299.9.1036 · Cited by 396
Lindsay, R., Scheele, W. H., Neer, R., Pohl, G., Adami, S., Mautalen, C., Reginster, J.-Y., Stepan, J. J., Myers, S. L., & Mitlak, B. H. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.18.2024 · Cited by 331
Lewiecki, E. M., Miller, P. D., McClung, M. R., Cohen, S. B., Bolognese, M. A., Liu, Y., Wang, A., Siddhanti, S., & Fitzpatrick, L. A. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070809 · Cited by 319
Self-citationEnsrud, K. E., Barrett-Connor, E. L., Schwartz, A., Santora, A. C., Bauer, D. C., Suryawanshi, S., Feldstein, A., Haskell, W. L., Hochberg, M. C., Torner, J. C., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040326 · Cited by 275
Fracture risk remains reduced one year after discontinuation of risedronate
Watts, N. B., Chines, A., Olszynski, W. P., McKeever, C. D., McClung, M. R., Zhou, X., & Grauer, A. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0460-7 · Cited by 237
Greenspan, S. L., Emkey, R. D., Bone, H. G., Weiss, S. R., Bell, N. H., Downs, R. W., McKeever, C., Miller, S. S., Davidson, M., Bolognese, M. A., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-11-200212030-00008 · Cited by 223
Self-citationPrince, R., Sipos, A., Hossain, A., Syversen, U., Ish-Shalom, S., Marcinowska, E., Halse, J., Lindsay, R., Dalsky, G. P., & Mitlak, B. H. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050501 · Cited by 207
Fracture Incidence in Relation to the Pattern of Use of Hormone Therapy in Postmenopausal Women
Banks, E. (2004) · JAMA · doi:10.1001/jama.291.18.2212 · Cited by 167
Changes in bone density and turnover after alendronate or estrogen withdrawal
Wasnich, R. D., Bagger, Y. Z., Hosking, D. J., McClung, M. R., Wu, M., Mantz, A. M., Yates, J., Ross, P. D., Alexandersen, P., Ravn, P., et al. (2004) · Menopause The Journal of The North American Menopause Society · doi:10.1097/01.gme.0000123641.76105.b5 · Cited by 127
Greendale, G. A., Espeland, M., Slone, S., Marcus, R., & Barrett-Connor, E. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.6.665 · Cited by 122
Gallagher, J. C., Rapuri, P. B., Haynatzki, G. R., & Detter, J. R. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020727 · Cited by 112
Self-citationYates, J., Barrett-Connor, E. L., Barlas, S., Chen, Y.-T., Miller, P. D., & Siris, E. S. (2004) · Obstetrics and Gynecology · doi:10.1097/01.aog.0000114986.14806.37 · Cited by 103
Self-citationNeele, S. J. M., Evertz, R., Roo, G. W. D. V.-D., Roos, J. C., & Netelenbos, J. C. (2002) · Bone · doi:10.1016/s8756-3282(01)00706-2 · Cited by 100
Ascott-Evans, B. H., Guañabens, N., Kivinen, S., Stuckey, B. G. A., Magaril, C., Vandormael, K., Stych, B., & Melton, M. E. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.7.789 · Cited by 86
Barrett-Connor, E. L., Wehren, L. E., Siris, E. S., Miller, P. B. W., Chen, Y.-T., Abbott, T. A., Berger, M. L., Santora, A. C., & Sherwood, L. M. (2003) · Menopause The Journal of The North American Menopause Society · doi:10.1097/01.gme.0000086467.82759.da · Cited by 76
Self-citationThe Waning Effect of Postmenopausal Estrogen Therapy on Osteoporosis
Ettinger, B. B., & Grady, D. G. (1993) · New England Journal of Medicine · doi:10.1056/nejm199310143291610 · Cited by 73
Effect of withdrawal of hormone replacement therapy on bone mass and bone turnover: the OFELY study
Sornay‐Rendu, E., Garnero, P., Munoz, F., Duboeuf, F., & Delmas, P. D. (2003) · Bone · doi:10.1016/s8756-3282(03)00171-6 · Cited by 54
Bone turnover in postmenopausal women after withdrawal of estrogen/gestagen replacement therapy
Thomsen, K., Riis, B. J., Johansen, J. S., Christiansen, C., & Røidbro, P. (1987) · Gynecological Endocrinology · doi:10.3109/09513598709030680 · Cited by 17
Cited by
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF), Kanis, J. A., Cooper, C., Rizzoli, R., & Reginster, J.-Y. (2019) · Osteoporosis International · doi:10.1007/s00198-018-4704-5 · Cited by 1,900
“values by 12–18 months, independently of the duration of treatment [261].”
BackgroundCamacho, P. M., Petak, S. M., Binkley, N., Diab, D. L., Eldeiry, L. S., Farooki, A., Harris, S. T., Hurley, D. L., Kelly, J., Lewiecki, E. M., et al. (2020) · Endocrine Practice · doi:10.4158/gl-2020-0524suppl · Cited by 1,182
Camacho, P. M., Petak, S. M., Binkley, N., Clarke, B. L., Harris, S. T., Hurley, D. L., Kleerekoper, M., Lewiecki, E. M., Miller, P. D., Narula, H. S., et al. (2016) · Endocrine Practice · doi:10.4158/ep161435.esgl · Cited by 1,140
Self-citationBone, H. G., Wagman, R. B., Brandi, M. L., Brown, J. P., Chapurlat, R., Cummings, S. R., Czerwiński, E., Fahrleitner-Pammer, A., Kendler, D. L., Lippuner, K., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30138-9 · Cited by 996
Self-citationEastell, R., Rosen, C. J., Black, D. M., Cheung, A. M., Murad, M. H., & Shoback, D. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00221 · Cited by 868
Metadata
- Authors
- Bone, H. G., Bolognese, M. A., Yuen, C. K., Kendler, D. L., Miller, P. D., Yang, Y.-C., Grazette, L., San Martin, J., & Gallagher, J. C.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2011-04
- Volume
- 96
- Issue
- 4
- Pages
- 972-980
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2134910437
- Cited by
- 623
- References
- 33
- FWCI
- 28.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.